Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain.
The latest migraine prevention guidelines will be presented at the American Academy of Neurology's annual meeting in New Orleans and published simultaneously in the journal Neurology.
Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed in the Orange Book in connection with Gralise (gabapentin tablets, 300 mg and 600 mg).
Tafamidis meglumine was approved in November 2011 for the treatment of transthyretin amyloidosis in adults. This rare disorder is caused by a defective gene and is associated with progressive nerve damage (neurological degeneration) that tafamidis is supposed to delay.
Concert Pharmaceuticals, Inc. and Fast Forward, LLC, the National Multiple Sclerosis Society's subsidiary devoted to bridging the gap between research and drug development, today announced a new collaboration to fund the preclinical advancement of C-21191, a deuterium-modified subtype-selective GABAA modulator developed by Concert with the therapeutic potential of treating spasticity and pain in multiple sclerosis (MS).
EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.
Santarus, Inc. and Depomed, Inc. today announced that they have entered into a settlement agreement with Lupin Ltd. and its subsidiary, Lupin Pharmaceuticals, Inc., to resolve pending patent litigation involving GLUMETZA 1000 mg and 500 mg.
Weight gain or loss may not always be caused by what you eat or how much you exercise. For some, it's the medicines you're taking.
Leading representatives of the American Epilepsy Society, American Academy of Neurology, and the Epilepsy Foundation today reported they have grave concerns about the implications and potential misuse of the anticonvulsant (AED) drug comparisons study recently released by the U.S. Agency for Health Research and Quality.
EpiCept Corporation today announced that it has filed for Fast Track designation for AmiKet(amitriptyline 4%, ketamine 2% cream) for the treatment for chemotherapy-induced peripheral neuropathy (CIPN) with the U.S. Food and Drug Administration.
XenoPort, Inc. announced today preliminary top-line results of a Phase 2, randomized, crossover clinical trial that compared optimized treatment with either Sinemet (immediate-release levodopa/carbidopa) or XP21279 co-formulated with carbidopa (279/CD) in advanced Parkinson's disease patients with motor fluctuations.
Hi-Tech Pharmacal Co., Inc. today reported results for the Company's fiscal second quarter ended October 31, 2011.
EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2011, and provided an update with respect to the Company's key business initiatives.
The American Academy of Neurology is releasing an updated guideline on how to best treat essential tremor, which is the most common type of tremor disorder and is often confused with other movement disorders such as Parkinson's disease.
New research presented this week highlights the ability of NextBio to help life scientists and clinicians investigate publicly available genomic data to assess biological mechanisms underlying drug toxicity, as well as discover prospective cancer biomarkers for further validation.
Hi-Tech Pharmacal Co., Inc. today reported results for the Company's fiscal first quarter ended July 31, 2011.
Santarus, Inc. and Depomed, Inc. today announced that they have entered into a new commercialization agreement for GLUMETZA (metformin hydrochloride extended release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement that the companies entered into in July 2008.
People who suffer headaches after a spinal tap might have a relatively simple way to ease the painful throb: a caffeine tablet.
In their two year study they found that there were no differences in changes in bone density or menopausal symptoms between women taking soy and those taking a placebo, although women taking isoflavones did have more hot flashes, Dr. Silvina Levis of the University of Miami and colleagues reported in the August 8/22 issue of Archives of Internal Medicine.
Ironwood Pharmaceuticals, Inc. and Depomed, Inc. today announced that Ironwood has licensed worldwide rights to utilize Depomed's Acuform gastric retentive drug delivery technology for an Ironwood early stage development program, continuing Ironwood's efforts to augment its development pipeline beyond linaclotide.
A fellow in the Breast Health Center at Women & Infants Hospital of Rhode Island was one of 25 nationwide to earn a 2011 Breast Cancer Symposium Merit Award from The Conquer Cancer Foundation of the American Society of Clinical Oncology.